Version history

{
  "session_id": "pan_0b9f67e3",
  "round_number": 1,
  "agent_persona": "persona-evidence-auditor",
  "agent_backend": "pantheon-stub",
  "action": "respond",
  "content": "## Evidence Quality Audit: Amyloid Cascade Hypothesis\n\n**Evidence Score: 0.62/1.0**\n\n### Quality Concerns Identified:\n\n1. **Citation Authenticity Issues**\n   - **Problem**: 2022 Science investigation revealed potentially manipulated images in influential 2006 Nature paper (Lesné et al.) proposing Aβ*56 oligomers as key toxic species\n   - **Impact**: ~2,300 citations to potentially compromised work; undermines specific oligomer-toxicity claims\n   - **Action**: MODIFY - core amyloid hypothesis survives, but specific Aβ*56 mechanism requires re-evaluation\n\n2. **Publication Bias & Selective Reporting**\n   - **Problem**: Decades of failed anti-amyloid trials (bapineuzumab, solanezumab, gantenerumab Phase III failures) were under-emphasized while positive preclinical data was over-represented\n   - **Effect Size**: Recent approved drugs (lecanemab, donanemab) show only modest clinical benefit (0.45-0.67 CDR-SB points over 18 months)\n   - **Action**: MODIFY - hypothesis partially validated but effect sizes much smaller than early literature suggested\n\n3. **Genetic Evidence Consistency**\n   - **Strength**: APP, PSEN1, PSEN2 mutations causing early-onset AD consistently increase Aβ42 production (>100 families, LOD scores >3.0)\n   - **Concern**: These represent <5% of AD cases; generalizability to sporadic AD unclear\n   - **Verdict**: ACCEPT genetic evidence as high-quality support for amyloid's causal role in familial AD\n\n4. **Temporal Relationship Evidence**\n   - **Strength**: Biomarker studies (DIAN, A4) show amyloid accumulation precedes tau and neurodegeneration by 10-20 years\n   - **Concern**: Correlation ≠ causation; amyloid could be parallel process rather than upstream trigger\n   - **Statistical Rigor**: Path analysis models show mixed results on whether amyloid mediates tau spread\n\n5. **Replication Crisis**\n   - **Problem**: Many foundational rodent studies showing dramatic cognitive rescue with amyloid clearance have failed to replicate in human trials\n   - **Action**: MODIFY - animal model predictions did not translate\n\n### Overall Verdict: **MODIFY**\n\nThe amyloid cascade hypothesis retains importance but requires substantial modification:\n\n**Accept:**\n- Amyloid plays *a* causal role (genetic evidence, biomarker trajectories, modest therapeutic efficacy)\n- Accumulation is necessary but insufficient for AD in most cases\n\n**Reject:**\n- Amyloid as sole or primary driver in sporadic AD\n- Magnitude of benefit from amyloid removal as initially predicted\n- Specific Aβ*56 oligomer mechanism from compromised 2006 work\n\n**Confidence in Evidence: 0.70**\n\nThe hypothesis remains scientifically important as:\n1. A validated therapeutic target (albeit with modest effect)\n2. Part of a multi-factorial model alongside tau, inflammation, vascular factors\n3. A cautionary tale about publication bias and image integrity in high-impact science\n\nRecommendation: Reframe from \"cascade\" to \"contributing factor\" in multifactorial neurodegeneration model.",
  "tokens_used": "0",
  "persona_id": "persona-evidence-auditor"
}